Molecular Partners AG
NASDAQ:MOLNBiotechnology
+$0.03 today
- Market cap
- $109.64M
- Beta
- 0.71
- P/E (TTM)
- -2.0
- EPS (TTM)
- -$1.55
Volume 0.00M
Average 0.00M
MOLN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Molecular Partners AGNASDAQ: MOLN
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of CHF 4.46M rose 9.3% year over year, ahead of the -3.8% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 22.4% from the prior quarter. Over 3 fiscal years it compounded at -12.0% a year.
Context
- Selling, general & admin increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 1 analysts of CHF 20.08M (+35.0%) for the fiscal year ending Dec 2026, a step up from the -13.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- CHF 4.46M+22.4% QoQ
- Last fiscal yearDec 2025
- CHF 14.87M-13.4% YoY
- LTMMar 2026
- CHF 16.11M-3.8% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
CHF · from the income statement
- Latest · FY2025
- 14.87M CHF
- Year-over-year change
- -13.4%
- 4-year CAGR
- -3.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 14.87M | -13.4% |
| FY2024 | 2024-12-31 | 17.16M | -9.6% |
| FY2023 | 2023-12-31 | 19M | -13.0% |
| FY2022 | 2022-12-31 | 21.82M | +29.1% |
| FY2021 | 2021-12-31 | 16.91M | — |
Selling, General & Admin vs competitors
How MOLN compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -3.8% is the 4th highest of 9, against a peer median of -5.0%.
- Over three fiscal years its annual growth of -12.0% compares with a peer median of -0.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.37M USD | -20.9% | -4.0% | 257.2% | |
| LTM Mar 2026 | $34.83M USD | -4.4% | -11.4% | 1952.5% | |
| LTM Mar 2026 | $25.06M USD | -19.7% | +4.0% | — | |
| LTM Mar 2026 | $22.56M USD | +1.9% | +16.6% | — | |
| LTM Mar 2026 | $19.01M USD | -17.8% | -9.7% | 599.8% | |
| LTM Mar 2026 | CHF 16.11M CHF | -3.8% | -12.0% | — | |
| LTM Mar 2026 | $15.52M USD | -5.5% | -6.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $13.7M USD | +20.3% | +31.5% | — |
| LTM Mar 2026 | $13.02M USD | +27.1% | +2.6% | 2479.6% | |
| Peer median (excluding MOLN) | — | -5.0% | -0.7% | 1276.2% | |
Competitors are the stored peer set for MOLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.33M | 189.56M | 7.04M | 4.97M | 0 |
| Cost of Revenue | 55.72M | 50.75M | 47.84M | 47.5M | 2.58M |
| Gross Profit | (46.39M) | 138.81M | (40.81M) | (42.53M) | (2.58M) |
| Gross Margin | -497.2% | 73.2% | -579.8% | -855.8% | — |
| Research & Development | 55.72M | 50.75M | 48.78M | 48.6M | 40.19M |
| Selling, General & Admin | 16.91M | 21.82M | 19M | 17.16M | 14.87M |
| Operating Expenses | 72.75M | 72.94M | 20.3M | 18.68M | 50.89M |
| Depreciation & Amortization | 2.57M | 2.39M | 2.42M | 2.37M | 2.14M |
| EBITDA | (60.66M) | 119M | (59.52M) | (51.65M) | (59.49M) |
| EBITDA Margin | -650.2% | 62.8% | -845.6% | -1039.2% | — |
| Operating Income | (63.42M) | 116.61M | (61.11M) | (61.22M) | (58.12M) |
| Operating Margin | -679.7% | 61.5% | -868.3% | -1231.7% | — |
| Interest Income | 108.28K | 1.2M | 4.28M | 3.38M | 1.52M |
| Interest Expense | 608.14K | 648.12K | 49K | 25K | 18K |
| Other Income / Expenses | (365K) | 1.24M | (876K) | 7.18M | (3.53M) |
| Income Before Tax | (63.78M) | 117.85M | (61.98M) | (54.04M) | (61.65M) |
| Pre-Tax Margin | -683.6% | 62.2% | -880.7% | -1087.3% | — |
| Income Tax Expense | 2K | 0 | 0 | 2K | 2K |
| Net Income | (63.79M) | 117.85M | (61.98M) | (54.04M) | (61.65M) |
| Net Margin | -683.7% | 62.2% | -880.7% | -1087.4% | — |
| EPS (Basic) | (2.06) | 3.63 | (1.89) | (1.59) | (1.65) |
| EPS (Diluted) | (2.06) | 3.54 | (1.89) | (1.59) | (1.65) |
| Weighted Avg Shares | 31.01M | 32.47M | 32.77M | 34.03M | 37.27M |
| Weighted Avg Shares (Diluted) | 31.01M | 33.27M | 32.77M | 34.03M | 37.27M |
Molecular Partners AG
NASDAQ:MOLN
Intrinsic Alpha fair value
Locked
Current Price
$2.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.